Vijay M Patil et al., 2022-07: Randomised open-label phase II trial in recurrent glioblastoma in which adding high-dose mebendazole to lomustine or temozolomide did not reach the pre-set 9-month survival benchmark.
The addition of MBZ to TMZ or CCNU failed to achieve the pre-set benchmark of 55% 9-month OS.
Vijay M Patil et al., 2022-07: Randomised open-label phase II trial in recurrent glioblastoma in which adding high-dose mebendazole to lomustine or temozolomide did not reach the pre-set 9-month survival benchmark. Study type: randomised open-label phase II trial, 88 patients randomised (44 per arm). Country: India (Tata Memorial Centre, Mumbai); registered CTRI/2018/01/011542. Dose: MBZ 800 mg three times daily with CCNU 110 mg/m2 every 6 weeks, or MBZ 1600 mg three times daily with TMZ 200 mg/m2 days 1-5 of a 28-day cycle, continued to progression; generic mebendazole isoform B (Tablet Mebex 100 mg, Cipla Limited) was used. Funder: Brain Tumor Foundation of India, Indian Cooperative Oncology Network, India Cancer Research Consortium under ICMR. Declared conflicts: V.P. reports research grants from BTF India, ICON and ICRC/ICMR. Comparator: the two combination arms against each other and against pre-set historical benchmarks (35%/55%), with no untreated control arm. 9-month OS was 36.6% (TMZ-MBZ) and 45% (CCNU-MBZ); there was no difference between arms (HR 0.98). This is the strongest null in vivo result in the record. Study type: randomized trial.
